Bavarian Nordic A/S (CPH:BAVA)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 13.55B |
| Revenue (ttm) | 6.07B |
| Net Income (ttm) | 1.12B |
| Shares Out | 77.81M |
| EPS (ttm) | 14.26 |
| PE Ratio | 12.22 |
| Forward PE | 10.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 465,545 |
| Average Volume | 436,858 |
| Open | 174.50 |
| Previous Close | 173.75 |
| Day's Range | 170.60 - 174.95 |
| 52-Week Range | 143.40 - 300.00 |
| Beta | 1.64 |
| RSI | 40.87 |
| Earnings Date | Mar 5, 2025 |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom... [Read more]
Financial Performance
Financial StatementsNews
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older
COPENHAGEN, Denmark, February 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Food and Drug Administration (FDA) has approved VIMKUNYA™ (Chikungunya Vaccine, Recombinant) for ...
Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025
COPENHAGEN, Denmark, February 3, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial results for 2024 and provided its financial guidance for 2025.
Bavarian Nordic – Completion of Share Buy-Back Program
COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 9, 2025, has now been completed, reachin...
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older
COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopte...
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
COPENHAGEN, Denmark, January 27, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase sha...
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
COPENHAGEN, Denmark, January 20, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase sha...
Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million
COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program of up to DKK 150 million as announced on December 11, 2024. The decisi...
Nigeria set to receive 11,200 doses of Mpox vaccine
The doses, manufactured by Bavarian Nordic, have been allocated to affected countries. The post Nigeria set to receive 11,200 doses of Mpox vaccine appeared first on Premium Times Nigeria .
Bavarian Nordic Inks Mpox Vaccine Deal With Serum Institute
Bavarian Nordic A/S agreed to a deal with the world’s largest vaccine manufacturer, the Serum Institute of India Pvt, to make the Danish biotech firm’s mpox shot.
Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India
COPENHAGEN, Denmark, December 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today a license and manufacturing agreement for its MVA-BN® mpox vaccine with Serum Institute of India Pvt. Ltd. (“SI...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding m...
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic
COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a new long-term incentive program for Executive Management...
Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program
COPENHAGEN, Denmark, December 11, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a share buy-back program of up to DKK 150 million in the first quarter of 2025. This decis...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, November 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding m...
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
COPENHAGEN, Denmark, November 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 218,750 as a consequence of employees' exe...
Bullish On Bavarian Nordic's Vaccine Portfolio And Revenue Potential In 2025
Bavarian Nordic's Mpox Moment Fades, But Diversification Shines
Bavarian Nordic's mpox vaccine sales have declined post-outbreak, causing reduced revenue and highlighting its reliance on outbreak-driven demand. The company's Travel Health segment demonstrated stre...
How one vaccine maker responded to a question about RFK Jr. as health secretary
Bavarian Nordic, a maker of the mpox vaccine, on Friday said the incoming Trump administration may present opportunities even after the announcement that noted vaccine skeptic Robert F. Kennedy Jr. ha...
Bavarian Nordic A/S (BVNKF) Q3 2024 Earnings Call Transcript
Bavarian Nordic A/S 2024 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Bavarian Nordic A/S in conjunction with their 2024 Q3 earnings call.
Bavarian Nordic reports results for first nine months; reaffirms upgraded guidance for FY24
Bavarian Nordic CEO says Kennedy nomination could fuel vaccine scepticism
Danish biotech Bavarian Nordic anticipates a boost in biodefense funding by the incoming U.S. administration despite concerns that the nomination of Robert F. Kennedy Jr. as health secretary could fue...
Bavarian Nordic has $340 mln orders for its mpox, smallpox vaccine in 2025
Danish biotech Bavarian Nordic said on Friday the order book for delivery of its vaccine for mpox and smallpox in 2025 currently totals around 2.40 billion crowns ($340 million), including previously ...
Bavarian Nordic Announces Interim Results for the First Nine Months of 2024
COPENHAGEN, Denmark, November 15, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2024 and business progress for the third quarter of ...
First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine
COPENHAGEN, Denmark, October 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN® mpox/smallpox vaccine in children 2 to 11 years of age.